Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma

Basit Öğe Kaydı
dc.authoridDagli, Adile Ferda/0000-0003-4077-4134
dc.authoridElkıran, Emin Tamer/0000-0001-6681-7249
dc.authoridharputluoglu, hakan/0000-0001-8537-5941
dc.authoridaksoy, asude/0000-0002-5609-9658
dc.authorwosidDagli, Adile Ferda/W-7878-2018
dc.authorwosidElkıran, Emin Tamer/ABI-8192-2020
dc.authorwosidharputluoglu, hakan/ABI-6451-2020
dc.contributor.authorAksoy, Asude
dc.contributor.authorElkiran, Emin Tamer
dc.contributor.authorHarputluoglu, Hakan
dc.contributor.authorDagli, Adile Ferda
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorUrakci, Zuhat
dc.date.accessioned2024-08-04T20:46:00Z
dc.date.available2024-08-04T20:46:00Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: To determine the prognostic value of excision repairs cross-complementation group1 (ERCC1) gene in cases with nasopharyngeal carcinoma (NPC) treated with platinum-containing chemotherapy (PCT). Subjects and Methods: The present study was included 33 cases in local advanced stage with NPC. ERCC1 expression was evaluated by using immunohistochemical staining in biopsy specimens. We evaluated the relationship between the degree of ERCC1 expression and clinicopathological features, response to therapy, survival rates in cases with NPC, retrospectively. Results: ERCC1 expression was not observed in 5 (15.15%) of all cases. Thirteen (39.9%) cases weakly positive (+1, +2) and 15 (45.5%) cases of all them were rather strongly positive (+3). There was no statistically significant difference between the degree of ERCC1 expression and clinicopathological features, response to treatment, survival rates (P 0.05) in cases with NPC. Conclusions: ERCC1 expression has no predictive value for survival in cases locally advanced stage with NPC. Evaluation of ERCC1 expression is not appropriate with a biomarker to detect cases who can benefit from PCT in NPC.en_US
dc.description.sponsorshipScientific Research Coordination Unit of Inonu University [2013/130]en_US
dc.description.sponsorshipThis study was supported by grants from the Scientific Research Coordination Unit of Inonu University (No: 2013/130).en_US
dc.identifier.doi10.4103/0973-1482.206865
dc.identifier.endpage555en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue3en_US
dc.identifier.pmid31169219en_US
dc.identifier.scopus2-s2.0-85067062546en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage550en_US
dc.identifier.urihttps://doi.org/10.4103/0973-1482.206865
dc.identifier.urihttps://hdl.handle.net/11616/98826
dc.identifier.volume15en_US
dc.identifier.wosWOS:000470851300017en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal of Cancer Research and Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectExcision repair cross-complementation group1en_US
dc.subjectnasopharyngeal carcinomaen_US
dc.subjectplatinum resistanceen_US
dc.subjectsurvivalen_US
dc.titleIs excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu